LAVA Therapeutics Q1 2023 Earnings Report

LAVA Therapeutics EPS Results

• Actual EPS: -$0.53
• Consensus EPS: -$0.49
• Beat/Miss: Missed by -$0.04
• One Year Ago EPS: N/A

LAVA Therapeutics Revenue Results

• Actual Revenue: $1.22 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

LAVA Therapeutics Announcement Details

• Quarter: Q1 2023
• Date: 6/8/2023
• Time: Q1 2023 Earnings Release

LAVA Therapeutics (NASDAQ:LVTX) N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.